Drug recall · February 15, 2017
Olanzapine tablets recall
Why: Failed impurities/degradation specifications: due to out-of-specification result for the Related Substance Compound C (Impurity 6 - N-Oxide at the 18 month stability station.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Olanzapine tablets, USP, 2.5 mg, packaged in a 30-count bottle, Rx only, Mfd: By: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-163-30
- Lots / codes
C500202
- Quantity
- 5,904 bottles
- Company
- Dr. Reddy's Laboratories, Inc., Princeton, NJ
- Distribution
- US Nationwide
- Initiated
- October 13, 2016 · Voluntary: Firm initiated
- Classified
- February 3, 2017
- Reported
- February 15, 2017
- Ended
- July 24, 2017
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Olanzapine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.